2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping

Key Result

CYP2C19 genotyping is inadequately recommended in the 2025 Acute Coronary Syndrome guidelines, representing a missed opportunity especially for patients at high bleeding risk.

Key Points

• Evaluate the role of CYP2C19 genotyping in managing acute coronary syndrome for patients at high bleeding risk.
• Review of existing guidelines regarding acute coronary syndrome management.
• Analysis of recommendations for CYP2C19 genotyping in high-risk populations.
• Identified lack of emphasis on CYP2C19 genotyping in current guidelines for acute coronary syndrome.
• Highlighted potential implications for patient safety and treatment efficacy.